Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASCO News In Brief: Glaxo Wellcome 506U

Executive Summary

Glaxo Wellcome 506U: Phase I 40-patient trial results show 9 complete remissions and three partial remissions out of 15 evaluable patients with acute T-cell lymphoblastic leukemia following treatment with 2-amino-methoxypurine arabinoside, 506U. Adverse reactions include dose-limiting neurotoxicity, mild-to-moderate nausea in one adult and mild conjunctivitis in two patients...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028196

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel